Full Press Release Details
Russell / Todd Fromer
212-781-5113 212-896-1250
Announces First Order from Major U.S. Hospital for Proprietary Water Filtration
Nephros enters the burgeoning water purification sector with a robust filtration
solution. Nephros initially targets medical institutions with its new Dual
Ultrafilters, to remove a broad range of contaminants from hospital water
YORK, January 12, 2006 - Nephros,
Inc. (AMEX: NEP) announced today that it has received its first Purchase
from a major hospital in New York City for its new water filtration device.
hospital has placed an initial order for Nephros' new Dual Stage Ultrafilter, or
DSU, a water filtration system that will be used initially in the hospital's
patient showers. The Nephros DSU represents a new and complimentary product
to Nephros' existing End Stage Renal Disease therapy business.
Nephros DSU incorporates the company's unique and proprietary dual stage filter
architecture. The Nephros DSU is designed to remove a broad range of bacteria,
viral agents and toxic substances, including salmonella,
hepatitis, HIV, Ebola virus, ricin toxin, legionella,
believes the DSU removes these harmful substances more effectively than other
water filters currently available.
an exciting diversification for us, and marks an important starting point
Nephros in further developing and marketing our unique new water filtration
Norman Barta, Nephros CEO. "Our research and development work on the OLp r
filter technologies for End Stage Renal Disease therapy provided us with
foundations for a proprietary multi-stage water filter that is cost effective,
extremely reliable, and long-lasting. Water contamination is a critical and
ongoing issue; the recent Katrina and Wilma storms drove that point home
clearly. We believe the Nephros DSU can offer a robust solution to a broad
of contaminated water problems. Hospitals are particularly stringent in their
water quality requirements; transplant patients and other individuals whose
immune systems are compromised can face a substantial infection risk in drinking
or bathing with standard tap water that would generally not present a danger
individuals with normal immune function. With over 5,000 registered hospitals
the United States alone, we believe the hospital shower and faucet market
offer us a valuable opportunity as a first step in water filtration." Nephros
has begun investigating a range of commercial, industrial and retail
opportunities for its DSU technology.
Inc., headquartered in New York, is a medical device company developing and
marketing products designed to improve the quality of life for the End-Stage
Renal Disease (ESRD) patient, while addressing the critical financial and
clinical needs of the care provider. Nephros also markets filtration products
complimentary to its core ESRD therapy business. ESRD is a disease state
characterized by the irreversible loss of kidney function. Nephros believes
its products are designed to remove a range of harmful substances more
effectively, and more cost-effectively, than existing ESRD treatment methods;
particularly with respect to substances known collectively as "middle
molecules," due to their molecular weight, that have been found to contribute
such conditions as dialysis related amyloidosis, carpal tunnel syndrome,
degenerative bone disease and ultimately, to mortality in the ESRD
release contains certain "forward-looking statements" within the meaning
Private Securities Litigation Reform Act of 1995, as amended. Such statements
may include statements regarding the efficacy and intended use of Nephros's
technologies, the timelines for bringing such products to market and the
availability of funding sources for continued development of such products
other statements that are not historical facts, including statements which
be preceded by the words "intends," "may," "will," "plans," "expects,"
"anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes,"
"potential" or similar words. For such statements, Nephros claims the protection
of the Private Securities Litigation Reform Act of 1995.
statements are not guarantees of future performance, are based on certain
assumptions and are subject to various known and unknown risks and
uncertainties, many of which are beyond the control of Nephros. Actual results
may differ materially from the expectations contained in the forward-looking
statements. Factors that may cause such differences include the risks that:
products, including the DSU technology, that appeared promising to Nephros
research or clinical trials may not demonstrate anticipated efficacy, safety
cost savings in subsequent pre-clinical or clinical trials; (ii) Nephros
obtain appropriate or necessary governmental approvals to achieve its business
plan or effectively market its products; (iii) product orders may be cancelled,
patients or customers currently using Nephros's products may cease to do so and
patients or customers expected to begin using Nephros's products may not; (iv)
Nephros's technology and products, including DSU technology, may not be accepted
in current or future target markets, which could lead to the failure to achieve
market penetration of Nephros's products; (v) Nephros may not be able to sell
its ESRD or water filtration products at competitive prices or profitably;
Nephros may not be able to secure or enforce adequate legal protection,
including patent protection, for its products; (vii) the reliability,
performance and endurance of Nephros' water filtration device and technology,
including its ability to remove a broad range of bacteria, viral agents and
toxic substances, may not be as effective as Nephros believes it to be; and
(viii) Nephros' water filtration technology may not achieve anticipated market
acceptance, including among hospitals, or that such technology may not be
suitable for other commercial, industrial or retail opportunities. More detailed
information about Nephros and the risk factors that may affect the realization
of forward-looking statements is set forth in Nephros's filings with the
Securities and Exchange Commission, including Nephros's Annual Report on Form
10-KSB filed with the SEC for the fiscal year ended December 31, 2004 and
Quarterly Report on Form 10-QSB filed with the SEC for the fiscal quarter
September 30, 2005. Investors and security holders are urged to read those
documents free of charge on the SEC's web site at www.sec.gov. Nephros does not
undertake to publicly update or revise its forward-looking statements as
result of new information, future events or otherwise.